ReviewInternational journal of general medicine2026
Gut-Brain Axis in Comorbid Constipation and Mood Disorders: Navigating the Efficacy-Tolerability Dilemma Through Emerging Evidence and Future Directions.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The comorbidity of constipation and mood disorders (anxiety/depression) creates a vicious cycle of symptom superposition and treatment resistance. The persistent "efficacy-tolerability" dilemma-whereby effective treatment for one condition may exacerbate the other-remains unresolved. Methods: This narrative review is based on a systematic search of PubMed, Embase, and Cochrane Library (2015-2026), focusing on epidemiology, gut-brain axis mechanisms, pharmacotherapy limitations, and emerging strategies. The search formula was: ("constipation" OR "functional constipation") AND ("mood disorders" OR "anxiety" OR "depression") AND ("gut-brain axis" OR "microbiota" OR "pharmacotherapy"). Results: Constipation and mood disorders show a bidirectional association, supported by recent Mendelian randomization studies. Pathogenesis involves central/enteric nervous system dysfunction, microbiota imbalance, and inflammatory mediators. Conventional drugs (eg, selective serotonin reuptake inhibitors [SSRIs], stimulant laxatives) may worsen one condition while treating the other. Preliminary evidence suggests gut-brain axis-targeted therapies-including 5-hydroxytryptamine type 4 (5-HT4) receptor agonists, psychobiotics, and multidisciplinary team models-may improve outcomes, but most findings remain exploratory. Conclusion: Overcoming the dilemma requires mechanism-oriented drug selection, optimized combination regimens, and individualized management. Future efforts should accelerate multi-target drug trials, multi-omics-based precision models, and multidisciplinary team implementation. The evidence base remains limited, with few large randomized controlled trials specifically targeting the comorbid population. Readers should interpret all quantitative estimates with caution, as they derive from heterogeneous study designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.